The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Abstract
BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer. METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival. RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P<0.001). CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach
McCulloch, P. G., Nita, M. E., Kazi, H. A., & Gama-Rodrigues, J. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001964.pub3 · Cited by 134
RetractedMacdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Extended Lymph-Node Dissection for Gastric Cancer
Bonenkamp, J. J., Hermans, J., Sasako, M., Welvaart, K., Songun, I., Meyer, S., Plukker, J. T. M., Van Elk, P., Obertop, H., Gouma, D. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401202 · Cited by 1,583
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459
for the Surgical Co-operative Group, Cuschieri, A., Weeden, S., Fielding, J., Bancewicz, J., Craven, J., Joypaul, V, Sydes, M., & Fayers, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690243 · Cited by 1,373
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Hartgrink, H. H., van de Velde, C. J. H., Putter, H., Bonenkamp, J. J., Klein Kranenbarg, E., Songun, I., Welvaart, K., van Krieken, J. H. J. M., Meijer, S., Plukker, J. T. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.026 · Cited by 918
Self-citationWebb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Self-citationRoss, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Self-citationPrognostic relevance of systematic lymph node dissection in gastric carcinoma
German Gastric Carcinoma Study Group, Siewert, J. R., Böttcher, K., Roder, J. D., Busch, R., Hermanek, P., & Meyer, H. J. (1993) · Journal of British Surgery · doi:10.1002/bjs.1800800829 · Cited by 452
Earle, C. C., & Maroun, J. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00076-3 · Cited by 411
Waters, J. S., Norman, A., Cunningham, D., Scarffe, J. H., Webb, A., Harper, P., Joffe, J. K., Mackean, M., Mansi, J., Leahy, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690350 · Cited by 275
Self-citationPrognostic relevance of systemic lymph node dissection in gastric carcinoma
Roukos, D. H., Baltogiannis, G., Cassioumis, D., Siewert, J. R., & Roder, J. D. (1995) · British journal of surgery · doi:10.1002/bjs.1800820954 · Cited by 275
Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N., Ford, H., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058932 · Cited by 257
Self-citationGastric cancer: a curable disease in Britain.
Sue-Ling, H. M., Johnston, D., Martin, I. G., Dixon, M. F., Lansdown, M. R., McMahon, M. J., & Axon, A. T. (1993) · BMJ · doi:10.1136/bmj.307.6904.591 · Cited by 254
Hartgrink, H. H., van de Velde, C. J. H., Putter, H., Songun, I., Tesselaar, M. E. T., Kranenbarg, E. K., de Vries, J. E., Wils, J. A., van der Bijl, J., & van Krieken, J. H. J. M. (2004) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2004.04.013 · Cited by 192
Self-citationSumpter, K., Harper-Wynne, C. L., Cunningham, D., Rao, S., Tebbutt, N. C., Norman, A. R., Ward, C., Iveson, T. J., Nicolson, M. C., Hickish, T., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602572 · Cited by 154
Self-citationMacdonald, J. S., Fleming, T. R., Peterson, R. F., Berenberg, J. L., McClure, S., Chapman, R., Eyre, H. J., Solanki, D. L., Cruz, A. B., Gagliano, R. G., et al. (1995) · Annals of Surgical Oncology · doi:10.1007/bf02307081 · Cited by 123
ADJUVANT CHEMOTHERAPY IN OPERABLE GASTRIC CANCER
Allum, W. H., Hallissey, M. T., Kelly, K., & British Stomach Cancer Group (1989) · The Lancet · doi:10.1016/s0140-6736(89)91607-3 · Cited by 99
Self-citationButler, T. M. (1876) · The Lancet · doi:10.1016/s0140-6736(02)49512-8 · Cited by 11
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Al-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32557-1 · Cited by 2,648
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Metadata
- Authors
- Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., & Chua, Y. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-07-06
- Volume
- 355
- Issue
- 1
- Pages
- 11-20
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115072149
- Cited by
- 6,334
- References
- 20
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.